Exploring potential opportunities in outpatient subcutaneous antimicrobial therapy (OSCAT).

At scPharmaceuticals we are evaluating the subcutaneous administration of ceftriaxone with a proprietary, on-body delivery system. Our goal is to provide the option of outpatient subcutaneous antibiotic therapy whereby the reliance of long-term intravenous catheters (and thus the complications with those catheters) are eliminated. Our subcutaneous ceftriaxone product is an investigational agent that has not been approved by any regulatory agency.